Personal tools

Coexpression cluster:C165

From FANTOM5_SSTAR

Jump to: navigation, search


Full id: C165_epithelioid_Adipocyte_mesothelioma_myxofibrosarcoma_lung_gastric_Mesothelial



Phase1 CAGE Peaks

Hg19::chr10:125605888..125605891,-p@chr10:125605888..125605891
-
Hg19::chr10:125605892..125605911,-p@chr10:125605892..125605911
-
Hg19::chr10:135129617..135129626,+p@chr10:135129617..135129626
+
Hg19::chr11:106426627..106426632,+p@chr11:106426627..106426632
+
Hg19::chr11:132618576..132618601,+p@chr11:132618576..132618601
+
Hg19::chr11:132618641..132618653,+p@chr11:132618641..132618653
+
Hg19::chr11:134820867..134820899,+p1@ENST00000528497
Hg19::chr11:89114727..89114730,+p@chr11:89114727..89114730
+
Hg19::chr12:54652060..54652084,-p16@CBX5
Hg19::chr13:24528588..24528596,+p@chr13:24528588..24528596
+
Hg19::chr13:27202938..27202944,-p@chr13:27202938..27202944
-
Hg19::chr14:100674067..100674074,-p@chr14:100674067..100674074
-
Hg19::chr14:64761083..64761101,-p1@ESR2
Hg19::chr14:64761275..64761283,-p14@ESR2
Hg19::chr15:95590268..95590274,-p@chr15:95590268..95590274
-
Hg19::chr16:11720946..11720960,-p@chr16:11720946..11720960
-
Hg19::chr16:11720965..11720989,-p@chr16:11720965..11720989
-
Hg19::chr16:11720992..11721005,-p@chr16:11720992..11721005
-
Hg19::chr16:85360152..85360165,+p@chr16:85360152..85360165
+
Hg19::chr17:40477088..40477101,-p24@STAT3
Hg19::chr17:46719983..46720028,+p@chr17:46719983..46720028
+
Hg19::chr17:46720055..46720064,+p@chr17:46720055..46720064
+
Hg19::chr17:46783984..46784023,+p@chr17:46783984..46784023
+
Hg19::chr17:7167279..7167298,-p@chr17:7167279..7167298
-
Hg19::chr17:8774055..8774068,-p@chr17:8774055..8774068
-
Hg19::chr17:8774126..8774143,-p@chr17:8774126..8774143
-
Hg19::chr18:18711938..18711943,-p@chr18:18711938..18711943
-
Hg19::chr18:43282521..43282533,-p@chr18:43282521..43282533
-
Hg19::chr18:56495029..56495073,+p@chr18:56495029..56495073
+
Hg19::chr18:61501808..61501812,+p@chr18:61501808..61501812
+
Hg19::chr19:31630560..31630583,-p@chr19:31630560..31630583
-
Hg19::chr19:54545613..54545621,-p@chr19:54545613..54545621
-
Hg19::chr19:54545670..54545677,-p@chr19:54545670..54545677
-
Hg19::chr19:54545692..54545704,-p@chr19:54545692..54545704
-
Hg19::chr19:54545761..54545772,-p@chr19:54545761..54545772
-
Hg19::chr19:54545780..54545792,-p@chr19:54545780..54545792
-
Hg19::chr19:54545810..54545821,-p@chr19:54545810..54545821
-
Hg19::chr19:54545833..54545844,-p@chr19:54545833..54545844
-
Hg19::chr19:54598154..54598171,+p@chr19:54598154..54598171
+
Hg19::chr19:54600897..54600899,+p@chr19:54600897..54600899
+
Hg19::chr19:6600819..6600831,-p@chr19:6600819..6600831
-
Hg19::chr1:233860206..233860221,+p1@BC032032
Hg19::chr1:233860255..233860261,+p2@BC032032
Hg19::chr1:240319887..240319892,+p@chr1:240319887..240319892
+
Hg19::chr1:240320047..240320058,+p@chr1:240320047..240320058
+
Hg19::chr21:32460330..32460336,-p@chr21:32460330..32460336
-
Hg19::chr21:32526965..32526979,-p@chr21:32526965..32526979
-
Hg19::chr21:32529607..32529639,-p@chr21:32529607..32529639
-
Hg19::chr21:45175275..45175288,+p@chr21:45175275..45175288
+
Hg19::chr2:107201761..107201766,+p@chr2:107201761..107201766
+
Hg19::chr2:172271476..172271479,+p@chr2:172271476..172271479
+
Hg19::chr2:173955327..173955334,+p26@ZAK
Hg19::chr2:173955472..173955479,+p17@ZAK
Hg19::chr2:173955485..173955502,+p19@ZAK
Hg19::chr2:173955505..173955510,+p30@ZAK
Hg19::chr2:178887106..178887129,+p@chr2:178887106..178887129
+
Hg19::chr2:220548381..220548386,+p@chr2:220548381..220548386
+
Hg19::chr2:75145535..75145551,+p4@ENST00000435984
Hg19::chr3:153575775..153575789,+p@chr3:153575775..153575789
+
Hg19::chr3:153587786..153587791,+p@chr3:153587786..153587791
+
Hg19::chr3:36170472..36170478,-p@chr3:36170472..36170478
-
Hg19::chr3:36170751..36170761,-p@chr3:36170751..36170761
-
Hg19::chr3:36170775..36170785,-p@chr3:36170775..36170785
-
Hg19::chr3:40101288..40101291,-p@chr3:40101288..40101291
-
Hg19::chr3:40118776..40118784,-p@chr3:40118776..40118784
-
Hg19::chr3:79552183..79552188,+p@chr3:79552183..79552188
+
Hg19::chr4:112993808..112993821,-p1@ENST00000511219
Hg19::chr4:138978577..138978584,+p1@ENST00000510066
Hg19::chr4:183750430..183750442,+p@chr4:183750430..183750442
+
Hg19::chr4:183750467..183750481,+p@chr4:183750467..183750481
+
Hg19::chr4:77378488..77378494,+p@chr4:77378488..77378494
+
Hg19::chr5:142023708..142023717,-p12@FGF1
Hg19::chr5:142023729..142023736,-p26@FGF1
Hg19::chr5:142023741..142023750,-p18@FGF1
Hg19::chr5:142023781..142023810,-p7@FGF1
Hg19::chr5:177989725..177989735,-p3@COL23A1
Hg19::chr6:142429681..142429688,-p@chr6:142429681..142429688
-
Hg19::chr7:137459538..137459553,-p5@DGKI
Hg19::chr7:137459557..137459587,-p3@DGKI
Hg19::chr7:157478953..157478987,-p@chr7:157478953..157478987
-
Hg19::chr7:32245227..32245235,+p@chr7:32245227..32245235
+
Hg19::chr7:68859601..68859605,+p@chr7:68859601..68859605
+
Hg19::chr7:80929708..80929725,+p@chr7:80929708..80929725
+
Hg19::chr8:100957024..100957046,+p@chr8:100957024..100957046
+
Hg19::chr8:41559667..41559679,-p@chr8:41559667..41559679
-
Hg19::chr8:67372487..67372498,+p14@C8orf46
Hg19::chr8:67372512..67372525,+p13@C8orf46
Hg19::chr8:67372527..67372543,+p11@C8orf46
Hg19::chr8:69770351..69770355,-p@chr8:69770351..69770355
-
Hg19::chr8:69961533..69961540,+p@chr8:69961533..69961540
+
Hg19::chr8:69961543..69961549,+p@chr8:69961543..69961549
+
Hg19::chr8:69961573..69961578,+p@chr8:69961573..69961578
+
Hg19::chr8:91072321..91072339,-p@chr8:91072321..91072339
-
Hg19::chr8:91110423..91110427,-p@chr8:91110423..91110427
-
Hg19::chr9:118595109..118595124,+p@chr9:118595109..118595124
+
Hg19::chr9:129142549..129142572,+p@chr9:129142549..129142572
+
Hg19::chr9:26171424..26171462,-p@chr9:26171424..26171462
-
Hg19::chr9:72658490..72658502,+p7@MAMDC2
Hg19::chr9:72658586..72658589,+p9@MAMDC2
Hg19::chr9:72658756..72658770,+p1@MAMDC2
Hg19::chr9:72658776..72658789,+p2@MAMDC2
Hg19::chr9:72833439..72833449,+p@chr9:72833439..72833449
+
Hg19::chr9:72841128..72841129,+p@chr9:72841128..72841129
+
Hg19::chr9:72841375..72841399,+p@chr9:72841375..72841399
+
Hg19::chrX:135338503..135338520,-p10@MAP7D3


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0005057receptor signaling protein activity0.00187153831806653
GO:0032147activation of protein kinase activity0.0142407650132369
GO:0030284estrogen receptor activity0.020902304528568
GO:0045860positive regulation of protein kinase activity0.020902304528568
GO:0033674positive regulation of kinase activity0.020902304528568
GO:0051347positive regulation of transferase activity0.020902304528568
GO:0007242intracellular signaling cascade0.0216310065997641
GO:0010369chromocenter0.0216310065997641
GO:0005062hematopoietin/interferon-class (D200-domain) cytokine receptor signal transducer activity0.025634107310511
GO:0045859regulation of protein kinase activity0.0289687346932396
GO:0043549regulation of kinase activity0.0289687346932396
GO:0051338regulation of transferase activity0.0289687346932396
GO:0043085positive regulation of catalytic activity0.0289687346932396
GO:0048523negative regulation of cellular process0.030519020041891
GO:0048519negative regulation of biological process0.030519020041891
GO:0030547receptor inhibitor activity0.030519020041891
GO:0048019receptor antagonist activity0.030519020041891
GO:0030545receptor regulator activity0.031699338724088
GO:0030520estrogen receptor signaling pathway0.031699338724088
GO:0000186activation of MAPKK activity0.031699338724088
GO:0005720nuclear heterochromatin0.0329309851972766
GO:0007165signal transduction0.0330777726270606
GO:0007243protein kinase cascade0.0348684891743291
GO:0004709MAP kinase kinase kinase activity0.0404629308483515
GO:0007154cell communication0.0404629308483515
GO:0008134transcription factor binding0.0404629308483515
GO:0000792heterochromatin0.0415797028128656
GO:0032502developmental process0.0415797028128656
GO:0007257activation of JNK activity0.041692835575608
GO:0000790nuclear chromatin0.0423177233929349
GO:0043507positive regulation of JNK activity0.0423177233929349
GO:0005515protein binding0.0423177233929349
GO:0043506regulation of JNK activity0.0423177233929349
GO:0000077DNA damage checkpoint0.0423177233929349
GO:0005634nucleus0.0436945181120922
GO:0031570DNA integrity checkpoint0.0447489183466585
GO:0004143diacylglycerol kinase activity0.0469213957622966
GO:0000776kinetochore0.0469213957622966
GO:0006953acute-phase response0.0471882062699121



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br><br>disease_data<br>

Disease
Ontology termp-valuen
epithelioid sarcoma5.42e-1951
mesenchymal cell neoplasm1.55e-982


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs



JASPAR motifs

Motifs-log10(p-value)
MA0003.10
MA0004.10.176213
MA0006.10.00853074
MA0007.10.260424
MA0009.10.298819
MA0014.12.49358e-09
MA0017.10.0179123
MA0019.10.0504923
MA0024.10.0515938
MA0025.10.46388
MA0027.11.42172
MA0028.10.000720034
MA0029.10.799574
MA0030.10.0539943
MA0031.10.605377
MA0038.11.91577
MA0040.10.215556
MA0041.10.206427
MA0042.10.00845154
MA0043.10.299173
MA0046.10.084519
MA0048.10.00941042
MA0050.10.157318
MA0051.10.83837
MA0052.10.060786
MA0055.10.000557334
MA0056.10
MA0057.12.915e-05
MA0058.10.20877
MA0059.10.119783
MA0060.139.5432
MA0061.10.893914
MA0063.10
MA0066.10.0986893
MA0067.10.265212
MA0068.10.929947
MA0069.10.082986
MA0070.11.98582
MA0071.10.471948
MA0072.10.265509
MA0073.13.27871e-15
MA0074.10.203604
MA0076.10.0118563
MA0077.10.0740083
MA0078.10.0161997
MA0081.10.322988
MA0083.10.307305
MA0084.10.403089
MA0087.10.262908
MA0088.10.272399
MA0089.10
MA0090.10.169578
MA0091.11.54199
MA0092.12.28578
MA0093.10.167315
MA0095.10
MA0098.10
MA0100.10.0382953
MA0101.14.21603
MA0103.10.0824658
MA0105.10.155476
MA0106.10.276641
MA0107.13.48354
MA0108.20.597985
MA0109.10
MA0111.10.193933
MA0113.10.0559966
MA0114.10.000321184
MA0115.10.215224
MA0116.10.0309439
MA0117.10.342325
MA0119.10.0204458
MA0122.10.752024
MA0124.10.189889
MA0125.10.142939
MA0130.10
MA0131.10.0189408
MA0132.10
MA0133.10
MA0135.10.682662
MA0136.10.221498
MA0139.10.00496791
MA0140.12.00205
MA0141.10.117335
MA0142.10.530469
MA0143.10.151498
MA0144.10.00797278
MA0145.10.00244934
MA0146.13.9007e-14
MA0147.10.00608857
MA0148.10.786455
MA0149.10.0195608
MA0062.21.24328e-05
MA0035.21.26347
MA0039.24.91999e-07
MA0138.20.377855
MA0002.20.00550477
MA0137.20.000841325
MA0104.20.00102503
MA0047.20.256341
MA0112.20.000139596
MA0065.20.000677449
MA0150.11.02295
MA0151.10
MA0152.10.483435
MA0153.10.134266
MA0154.10.00630179
MA0155.10.0190879
MA0156.10.132403
MA0157.10.757372
MA0158.10
MA0159.10.0640183
MA0160.10.244856
MA0161.10
MA0162.17.95304e-07
MA0163.14.77667e-08
MA0164.15.98855
MA0080.20.897349
MA0018.20.136257
MA0099.22.48588
MA0079.20
MA0102.20.432633
MA0258.10.0554076
MA0259.10.0186401
MA0442.10



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)

TF#promotersEnrichmentp-valueq-value
NFYA#4800172.983189256163045.08516815361666e-050.000866378265571893
NFYB#4801152.394256179076640.001442698631975080.00925175011819016



Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=Coexpression_cluster:C165&oldid=3067283"